2 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 2 Phase 3, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow HEPATITIS C VIRUS CHRONIC INFECTION: new trials by email Literature Review of HEPATITIS C VIRUS CHRONIC INFECTION trials Research Report on HEPATITIS C VIRUS CHRONIC INFECTION
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study). resveratrol, quercetin, taurine, whey protein, and inulin, whey protein - Liver Disease Chronic, HEPATITIS C VIRUS CHRONIC INFECTION | Not applicable | Recruiting | University of Guadalajara | 26 | 2025-10-11 | 2026-03-23 |
| C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir - HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic | Phase 3 | Active not recruiting | Atea Pharmaceuticals, Inc. | 880 | 2025-06-02 | 2026-06-29 |
| Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada Preimplementation of HCV Point of care testing - HCV, HEPATITIS C VIRUS CHRONIC INFECTION | Recruiting | McGill University | 300 | 2025-05-20 | 2025-07-31 | |
| C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (SOF/VEL) - HEPATITIS C VIRUS CHRONIC INFECTION | Phase 3 | Completed | Atea Pharmaceuticals, Inc. | 940 | 2025-04-07 | 2026-10-29 |
| Hepatitis Inequalities Study Chronic Hepatitis B, HEPATITIS C VIRUS CHRONIC INFECTION | Not yet recruiting | Chinese University of Hong Kong | 100000 | 2024-10-01 | 2024-09-19 | |
| Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma CP 675,206 - Hepatocellular Carcinoma, Hepatitis C Virus Chronic Infection | Phase 2 | Completed | Clinica Universidad de Navarra, Universidad de Navarra | 20 | 2008-12-01 | 2012-06-08 |
| Prediction of Response to Treatment of Patients With Chronic HCV Infection by Genetic Profile Hepatitis C Virus Chronic Infection | Unknown | Hadassah Medical Organization | 150 | 2006-03-01 | 2006-01-06 |
Hepatitis C (2) · Carcinoma, Hepatocellular (1) · Communicable Diseases (1) · Frailty (1) · Hepatitis B, Chronic (1) · Hepatitis C, Chronic (1)
Digestive System Diseases (4) · Infections (4) · Liver Diseases (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Blood-Borne Infections (3) · Communicable Diseases (3) · Disease Attributes (3) · Hepatitis (3) · Hepatitis, Viral, Human (3) · Virus Diseases (3) · Chronic Disease (2) · Flaviviridae Infections (2) · Hepatitis, Chronic (2) · RNA Virus Infections (2)
sofosbuvir-velpatasvir drug combination (2) · Inulin (1) · Quercetin (1) · Resveratrol (1) · Taurine (1) · Whey Proteins (1)
Atea Pharmaceuticals, Inc. (2) · Chinese University of Hong Kong (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Hadassah Medical Organization (1) · McGill University (1) · University of Guadalajara (1)
Canada (2) · Spain (2) · Egypt (1) · France (1) · Germany (1) · Greece (1) · India (1) · Israel (1) · Malaysia (1) · Mexico (1) · Moldova (1) · Pakistan (1) · Poland (1) · Romania (1) · South Africa (1)
Guillaume Fontaine, RN, PhD (1) · Yaron Ilan, MD (1)
PMID 19638084, PMID 22419935, PMID 23466307, PMID 25311610, PMID 25577300, PMID 26621580, PMID 28820468, PMID 29105115, PMID 29779170, PMID 30136291, PMID 39032786, PMID 41408357